| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| The Americas | Region | 2025 | USD | 27,557.0 | 46.9% |
| Europe excluding the United Kingdom | Region | 2025 | USD | 13,455.0 | 22.9% |
| Asia, Africa And Australasia | Region | 2025 | USD | 13,368.0 | 22.8% |
| UNITED KINGDOM | Region | 2025 | USD | 4,359.0 | 7.4% |
| Total Oncology | Product | 2025 | USD | 23,698.0 | 23.9% |
| CVRM | Product | 2025 | USD | 12,764.0 | 12.9% |
| Rare Disease | Product | 2025 | USD | 9,126.0 | 9.2% |
| Farxiga | Product | 2025 | USD | 8,400.0 | 8.5% |
| Tagrisso | Product | 2025 | USD | 7,254.0 | 7.3% |
| Imfinzi | Product | 2025 | USD | 6,063.0 | 6.1% |
| Ultomiris | Product | 2025 | USD | 4,718.0 | 4.8% |
| Calquence | Product | 2025 | USD | 3,518.0 | 3.6% |
| Lynparza | Product | 2025 | USD | 3,279.0 | 3.3% |
| Symbicort | Product | 2025 | USD | 2,885.0 | 2.9% |
| Fasenra | Product | 2025 | USD | 1,981.0 | 2.0% |
| Soliris | Product | 2025 | USD | 1,837.0 | 1.9% |
| Enhertu | Product | 2025 | USD | 1,798.0 | 1.8% |
| Strensiq | Product | 2025 | USD | 1,678.0 | 1.7% |
| Crestor | Product | 2025 | USD | 1,216.0 | 1.2% |
| Breztri | Product | 2025 | USD | 1,199.0 | 1.2% |
| Zoladex | Product | 2025 | USD | 1,106.0 | 1.1% |
| Total Other medicines | Product | 2025 | USD | 972.0 | 1.0% |
| Brilinta | Product | 2025 | USD | 823.0 | 0.8% |
| Nexium | Product | 2025 | USD | 816.0 | 0.8% |
| Lokelma | Product | 2025 | USD | 698.0 | 0.7% |
| Saphnelo | Product | 2025 | USD | 686.0 | 0.7% |
| Koselugo | Product | 2025 | USD | 662.0 | 0.7% |
| Pulmicort | Product | 2025 | USD | 518.0 | 0.5% |
| Oncology, Others | Product | 2025 | USD | 425.0 | 0.4% |
| Synagis | Product | 2025 | USD | 292.0 | 0.3% |
| Roxadustat | Product | 2025 | USD | 274.0 | 0.3% |
| FluMist | Product | 2025 | USD | 272.0 | 0.3% |
| Other, Others | Product | 2025 | USD | 156.0 | 0.2% |
| Total Oncology | Product | 2023 | USD | 17,145.0 | 21.4% |
| CVRM | Product | 2023 | USD | 10,585.0 | 13.2% |
| Rare Disease | Product | 2023 | USD | 7,764.0 | 9.7% |
| Farxiga | Product | 2023 | USD | 5,963.0 | 7.4% |
| Tagrisso | Product | 2023 | USD | 5,799.0 | 7.2% |
| Imfinzi | Product | 2023 | USD | 4,237.0 | 5.3% |
| Soliris | Product | 2023 | USD | 3,145.0 | 3.9% |
| Ultomiris. | Product | 2023 | USD | 2,965.0 | 3.7% |
| Lynparza | Product | 2023 | USD | 2,811.0 | 3.5% |
| Calquence | Product | 2023 | USD | 2,514.0 | 3.1% |
| Symbicort | Product | 2023 | USD | 2,362.0 | 2.9% |
| Fasenra | Product | 2023 | USD | 1,553.0 | 1.9% |
| Brilinta | Product | 2023 | USD | 1,324.0 | 1.7% |
| Total Other medicines | Product | 2023 | USD | 1,176.0 | 1.5% |
| Strensiq | Product | 2023 | USD | 1,152.0 | 1.4% |
| Crestor | Product | 2023 | USD | 1,107.0 | 1.4% |
| Enhertu | Product | 2023 | USD | 1,022.0 | 1.3% |
| Zoladex | Product | 2023 | USD | 952.0 | 1.2% |
| Nexium | Product | 2023 | USD | 945.0 | 1.2% |
| Pulmicort | Product | 2023 | USD | 713.0 | 0.9% |
| Breztri | Product | 2023 | USD | 677.0 | 0.8% |
| Seloken/Toprol-XL | Product | 2023 | USD | 640.0 | 0.8% |
| Synagis | Product | 2023 | USD | 546.0 | 0.7% |
| Lokelma | Product | 2023 | USD | 412.0 | 0.5% |
| Koselugo | Product | 2023 | USD | 331.0 | 0.4% |
| Faslodex | Product | 2023 | USD | 297.0 | 0.4% |
| Saphnelo | Product | 2023 | USD | 280.0 | 0.4% |
| Roxadustat | Product | 2023 | USD | 271.0 | 0.3% |
| Other, Others | Product | 2023 | USD | 231.0 | 0.3% |
| Onglyza | Product | 2023 | USD | 227.0 | 0.3% |
| Oncology, Others | Product | 2023 | USD | 224.0 | 0.3% |
| FluMist | Product | 2023 | USD | 216.0 | 0.3% |
| Andexxa | Product | 2023 | USD | 182.0 | 0.2% |
| Kanuma | Product | 2023 | USD | 171.0 | 0.2% |
| Bydureon | Product | 2023 | USD | 163.0 | 0.2% |
| Bevespi | Product | 2023 | USD | 58.0 | 0.1% |
| Daliresp/Daxas | Product | 2023 | USD | 54.0 | 0.1% |
| Vaxzevria | Product | 2023 | USD | 12.0 | 0.0% |
| Total Oncology | Product | 2022 | USD | 14,631.0 | 18.6% |
| CVRM | Product | 2022 | USD | 9,188.0 | 11.7% |
| Rare Disease | Product | 2022 | USD | 7,053.0 | 9.0% |
| BioPharmaceuticals: total Respiratory & Immunology | Product | 2022 | USD | 5,765.0 | 7.3% |
| Tagrisso | Product | 2022 | USD | 5,444.0 | 6.9% |
| Farxiga | Product | 2022 | USD | 4,381.0 | 5.6% |
| Soliris | Product | 2022 | USD | 3,762.0 | 4.8% |
| Imfinzi | Product | 2022 | USD | 2,784.0 | 3.5% |
| Lynparza | Product | 2022 | USD | 2,638.0 | 3.4% |
| Symbicort | Product | 2022 | USD | 2,538.0 | 3.2% |
| Calquence | Product | 2022 | USD | 2,057.0 | 2.6% |
| Ultomiris. | Product | 2022 | USD | 1,965.0 | 2.5% |
| Vaxzevria | Product | 2022 | USD | 1,798.0 | 2.3% |
| Total Other medicines | Product | 2022 | USD | 1,625.0 | 2.1% |
| Fasenra | Product | 2022 | USD | 1,396.0 | 1.8% |
| Brilinta | Product | 2022 | USD | 1,358.0 | 1.7% |
| Nexium | Product | 2022 | USD | 1,285.0 | 1.6% |
| Crestor | Product | 2022 | USD | 1,048.0 | 1.3% |
| Strensiq | Product | 2022 | USD | 958.0 | 1.2% |
| Zoladex | Product | 2022 | USD | 927.0 | 1.2% |
| Seloken/Toprol-XL | Product | 2022 | USD | 862.0 | 1.1% |
| Pulmicort | Product | 2022 | USD | 645.0 | 0.8% |
| Synagis | Product | 2022 | USD | 578.0 | 0.7% |
| Respiratory, Others | Product | 2022 | USD | 421.0 | 0.5% |
| Breztri | Product | 2022 | USD | 398.0 | 0.5% |
| Other, Others | Product | 2022 | USD | 340.0 | 0.4% |
| Faslodex | Product | 2022 | USD | 334.0 | 0.4% |
| Lokelma | Product | 2022 | USD | 289.0 | 0.4% |
| Bydureon | Product | 2022 | USD | 280.0 | 0.4% |
| Onglyza | Product | 2022 | USD | 257.0 | 0.3% |
| Koselugo | Product | 2022 | USD | 208.0 | 0.3% |
| Roxadustat | Product | 2022 | USD | 197.0 | 0.3% |
| Daliresp/Daxas | Product | 2022 | USD | 189.0 | 0.2% |
| FluMist | Product | 2022 | USD | 175.0 | 0.2% |
| Kanuma | Product | 2022 | USD | 160.0 | 0.2% |
| Andexxa | Product | 2022 | USD | 150.0 | 0.2% |
| Saphnelo | Product | 2022 | USD | 116.0 | 0.2% |
| Iressa | Product | 2022 | USD | 114.0 | 0.1% |
| Arimidex | Product | 2022 | USD | 99.0 | 0.1% |
| Enhertu | Product | 2022 | USD | 79.0 | 0.1% |
| Casodex | Product | 2022 | USD | 78.0 | 0.1% |
| Bevespi | Product | 2022 | USD | 58.0 | 0.1% |
| Oncology, Others | Product | 2022 | USD | 44.0 | 0.1% |
| Ophatys | Product | 2022 | USD | 33.0 | 0.0% |
| Nexium | Product | 2021 | USD | 1,326.0 | 30.3% |
| Crestor | Product | 2021 | USD | 1,096.0 | 25.1% |
| Zoladex | Product | 2021 | USD | 948.0 | 21.7% |
| Lynparza/Koselugo | Product | 2021 | USD | 400.0 | 9.1% |
| Profit share revenue from product sales by collaboration partners | Product | 2021 | USD | 200.0 | 4.6% |
| Roxadustat | Product | 2021 | USD | 174.0 | 4.0% |
| Royal income | Product | 2021 | USD | 138.0 | 3.2% |
| Other Ongoing Collaboration Revenue | Product | 2021 | USD | 64.0 | 1.5% |
| Enhertu | Product | 2021 | USD | 17.0 | 0.4% |
| Collaboration Revenue | Product | 2021 | USD | 12.0 | 0.3% |
| Crestor | Product | 2020 | USD | 1,180.0 | 44.8% |
| Zoladex | Product | 2020 | USD | 888.0 | 33.7% |
| Lynparza And Koselugo | Product | 2020 | USD | 460.0 | 17.5% |
| Royal Revenue | Product | 2020 | USD | 62.0 | 2.4% |
| Other Collaboration Revenue | Product | 2020 | USD | 46.0 | 1.8% |
| Oncology Products | Product | 2019 | USD | 8,667.0 | 18.4% |
| Cardiovascular And Metabolic Diseases Products | Product | 2019 | USD | 6,906.0 | 14.7% |
| Respiratory Products | Product | 2019 | USD | 5,391.0 | 11.4% |
| Tagrisso | Product | 2019 | USD | 3,189.0 | 6.8% |
| Other Products | Product | 2019 | USD | 2,601.0 | 5.5% |
| Symbicort | Product | 2019 | USD | 2,495.0 | 5.3% |
| Brilinta | Product | 2019 | USD | 1,581.0 | 3.4% |
| Farxiga | Product | 2019 | USD | 1,543.0 | 3.3% |
| Nexium | Product | 2019 | USD | 1,483.0 | 3.2% |
| Imfinzi | Product | 2019 | USD | 1,469.0 | 3.1% |
| Pulmicort | Product | 2019 | USD | 1,466.0 | 3.1% |
| Crestor | Product | 2019 | USD | 1,278.0 | 2.7% |
| Lynparza | Product | 2019 | USD | 1,198.0 | 2.5% |
| Faslodex | Product | 2019 | USD | 892.0 | 1.9% |
| Zoladex | Product | 2019 | USD | 813.0 | 1.7% |
| Seloken Toprol Xl | Product | 2019 | USD | 760.0 | 1.6% |
| Fasenra | Product | 2019 | USD | 704.0 | 1.5% |
| Bydureon | Product | 2019 | USD | 549.0 | 1.2% |
| Onglyza | Product | 2019 | USD | 527.0 | 1.1% |
| Iressa | Product | 2019 | USD | 423.0 | 0.9% |
| Other Respiratory Products | Product | 2019 | USD | 390.0 | 0.8% |
| Synagis | Product | 2019 | USD | 358.0 | 0.8% |
| Other Products Others | Product | 2019 | USD | 306.0 | 0.7% |
| Other Cardiovascular And Metabolic Diseases Products | Product | 2019 | USD | 271.0 | 0.6% |
| Losec Prilosec | Product | 2019 | USD | 263.0 | 0.6% |
| Arimidex | Product | 2019 | USD | 225.0 | 0.5% |
| Atacand | Product | 2019 | USD | 221.0 | 0.5% |
| Daliresp Daxas | Product | 2019 | USD | 215.0 | 0.5% |
| Casodex | Product | 2019 | USD | 200.0 | 0.4% |
| Seroquel Xr Ir | Product | 2019 | USD | 191.0 | 0.4% |
| Calquence | Product | 2019 | USD | 164.0 | 0.4% |
| Byetta | Product | 2019 | USD | 110.0 | 0.2% |
| Other Oncology Products | Product | 2019 | USD | 94.0 | 0.2% |
| Duaklir | Product | 2019 | USD | 77.0 | 0.2% |
| Other Diabetes | Product | 2019 | USD | 52.0 | 0.1% |
| Bevespi | Product | 2019 | USD | 42.0 | 0.1% |
| Lokelma | Product | 2019 | USD | 14.0 | 0.0% |
| Breztri | Product | 2019 | USD | 2.0 | 0.0% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
